EGFR and lung cancer: Using serial CTC samples from lung cancer patients, Maheswaran et al. demonstrated evolution of T790M and other epidermal growth factor receptor (EGFR)-activating mutations during treatment with the tyrosine kinase inhibitor, Gefitinib [20].